Vertex Pharma (VRTX) – StreetInsider.com Reports
-
Vertex Pharma (VRTX) Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
-
Vertex Pharma (VRTX) Receives CHMP Positive Opinion for KALYDECO
-
Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick
-
Wolfe Research Starts Vertex (VRTX) at Outperform
-
Vertex (VRTX) PT Raised to $465 at Argus
-
Vertex (VRTX) PT Lowered to $371 at Canaccord Genuity
-
Vertex (VRTX) PT Lowered to $498 at UBS
-
Vertex (VRTX) PT Raised to $450 at JPMorgan
-
Vertex (VRTX) PT Raised to $420 at RBC Capital
-
Evercore ISI Downgrades Vertex (VRTX) to In Line Citing Valuation
-
Vertex (VRTX) PT Raised to $457 at H.C. Wainwright
-
Vertex (VRTX) PT Raised to $550 at BofA Securities
-
Vertex (VRTX) PT Raised to $440 at Jefferies
-
Vertex (VRTX) PT Raised to $472 at Barclays
-
Vertex Pharma (VRTX) Tops Q4 EPS by 13c, offers guidance
-
Vertex Pharma (VRTX) Reports Positive Results From Trials of Vanzacaftor/Tezacaftor/Deutivacaftor
-
Bernstein Downgrades Vertex (VRTX) to Market Perform Citing Full Valuation
-
Vertex (VRTX) PT Raised to $438 at JPMorgan
-
Vertex (VRTX) PT Lowered to $378 at Canaccord Genuity
-
Vertex (VRTX) PT Raised to $500 at Oppenheimer
-
Maxim Group Downgrades Vertex (VRTX) to Hold
-
Vertex (VRTX) PT Raised to $508 at Truist Securities
-
Vertex (VRTX) PT Raised to $559 at Goldman Sachs
-
Baird Downgrades Vertex (VRTX) to Neutral
-
Vertex non-opioid painkiller meets main goal in late-stage trials
-
Vertex Pharma (VRTX) Reports Positive Results From the VX-548 Phase 3 Program
-
Vertex (VRTX) PT Raised to $450 at Oppenheimer
-
Vertex (VRTX) PT Raised to $440 at Cantor Fitzgerald
-
Canaccord Genuity Downgrades Vertex (VRTX) to Sell, 'Pain data likely to be positive, but better-than-our- best-case already priced in...'
-
Vertex (VRTX) PT Raised to $397 at RBC Capital
-
Vertex Pharma (VRTX) Announces US FDA Approval of CASGEVY for Treatment of Transfusion-Dependent Beta Thalassemia
-
European stocks rise ahead of key US CPI; Tesco lifts profit guidance
-
European stocks rise ahead of key US CPI; Tesco lifts profit guidance
-
Biotech top picks - Bernstein
-
Vertex Pharma (VRTX) Announces Approval of CASGEVY in Saudi Arabia
-
Vertex (VRTX) PT Raised to $425 at TD Cowen
-
Vertex (VRTX) PT Raised to $430 at Oppenheimer
-
Vertex Pharma (VRTX) Issues Pipeline and Business Updates
-
Vertex (VRTX) PT Raised to $436 at Evercore ISI
-
Morgan Stanley sees this pharma stock rising 4% in early 2024
-
Vertex (VRTX) PT Raised to $445 at Guggenheim
-
Vertex Pharma (VRTX) Reports Positive CHMP Opinion for CASGEVY
-
William O'Neil Starts Vertex (VRTX) at Buy
-
Vertex (VRTX) PT Raised to $500 at Wells Fargo
-
Vertex (VRTX) PT Raised to $379 at RBC Capital
-
Midday movers: Pfizer, Etsy, and more
-
Vertex (VRTX) positive chronic pain data 'unlocks $9bn+ TAM' - Goldman Sachs
-
Vertex Pharma (VRTX) Climbs 7% Following Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
-
Vertex Pharma (VRTX) Reports Positive Results From Phase 2 Study of VX-548
-
Vertex Pharma (VRTX) Presents Positive Results from Pivotal Trials of CASGEVY
Back to VRTX Stock Lookup